Stellular Bio Secures Funding to Advance 'Off-the-Shelf' Regenerative Eye Therapy

WATERTOWN, Mass. – January 28, 2026 – Stellular Bio, a biotechnology firm pioneering a new class of regenerative medicines, announced today the closing of its Series 1 financing round. The investment, led by Ziff Capital Partners with participation from Cockrell Interests, is earmarked to propel the company's lead candidate, STLR-201, into clinical trials for the treatment of severe dry eye associated with Sjogren's disease.

The financing marks a significant vote of confidence in Stellular's novel Platelet-derived Regenerative Biologic (PRB) platform, which aims to transform complex, patient-specific regenerative treatments into standardized, "off-the-shelf" therapies accessible to a broad population. For the millions suffering from debilitating autoimmune conditions, this development could signal a new era of treatment.

A New Hope for a Debilitating Condition

Sjogren's disease is a systemic autoimmune disorder where the body's immune system mistakenly attacks its own moisture-producing glands. While it can affect the entire body, one of its most prominent and life-altering symptoms is severe dry eye, or keratoconjunctivitis sicca. In the United States alone, an estimated four million people live with Sjogren's, and according to the Sjögren's Foundation, a staggering 75 percent of them report that the constant dryness, irritation, and pain in their eyes has a moderate to major impact on their daily lives.

For these patients, simple activities like reading, driving, or working on a computer can become excruciating. Left untreated, the chronic inflammation and lack of tear production can lead to serious complications, including corneal damage, ulcers, and even vision loss. Current treatments primarily focus on managing symptoms with artificial tears or using anti-inflammatory drugs to quell the immune response.

While more advanced therapies exist, they often come with significant logistical hurdles. Treatments derived from a patient's own blood, such as platelet-rich plasma (PRP) eye drops, have shown considerable promise in clinical studies for their regenerative capabilities. However, these autologous therapies must be prepared individually for each patient from their own blood draw, a process that is not only cumbersome and expensive but can also lead to inconsistencies between batches. This lack of standardization has largely confined such powerful regenerative approaches to specialized clinics, leaving a vast unmet need for a scalable and reliable solution.

The 'Goldilocks' Solution: Standardizing Regenerative Medicine

Stellular Bio believes its lead candidate, STLR-201, is the answer. Derived from platelet-progenitor stem cells, the therapy is designed to be a consistent, mass-produced biologic that delivers the healing potential of platelet-derived growth factors without the need for individual patient processing. This "off-the-shelf" approach could democratize access to regenerative medicine for ocular surface diseases.

The company's technology is built upon a robust body of scientific evidence demonstrating the efficacy of platelet-derived products in ophthalmology. Peer-reviewed research, including studies published in the British Journal of Ophthalmology and the Journal of Clinical Medicine, has repeatedly shown that the growth factors and anti-inflammatory molecules concentrated in platelets can improve tear production, reduce corneal damage, and alleviate symptoms in patients with severe dry eye. The primary obstacle identified in this research has been the variability of preparation. Stellular's innovation lies in its manufacturing process, which is engineered to produce a standardized, quality-controlled therapeutic that can be prescribed like any other approved medicine.

"PRBs are Goldilocks-like treatments that combine the regenerative potential and inherent polypharmacology of plasma and cell therapies with the reproducibility and economy of scale of traditional biologics," stated Stellular CEO Derek Adams in the announcement. Adams, whose extensive background includes leadership roles in manufacturing and technical operations at bluebird bio and Alexion Pharmaceuticals, brings critical expertise in scaling complex biologic production—a key factor for realizing the company's vision.

STLR-201 aims to simultaneously modulate the multiple cell and tissue types affected in ocular surface disease, offering a multifaceted healing mechanism that goes beyond simple symptom relief. If successful in clinical trials, it would represent a paradigm shift from bespoke, procedure-based treatments to a widely available pharmaceutical product.

Strategic Capital Fuels Clinical Advancement

The backing from Ziff Capital Partners and Cockrell Interests is more than just financial fuel; it is a strategic endorsement of Stellular's platform. Ziff Capital Partners, a venture firm with a keen eye for disruptive life science technologies, has a history of investing in the platelet space, including a prior investment in a company focused on producing donor-independent platelets from stem cells. This background suggests a deep understanding of the technology's potential and the challenges in the field, making their lead investment a powerful validation of Stellular's approach.

The capital will be instrumental in navigating the rigorous regulatory pathway ahead. As a novel biologic, STLR-201 will be overseen by the FDA's Center for Biologics Evaluation and Research (CBER). Stellular will need to conduct comprehensive clinical trials to prove the safety and efficacy of its product, a costly and time-intensive process. However, given the significant unmet need in Sjogren's disease, the therapy could potentially be eligible for expedited regulatory programs designed to speed the development of treatments for serious conditions.

The successful Series 1 round provides Stellular with the necessary runway to generate this crucial clinical data and move STLR-201 closer to becoming a reality for patients.

Beyond the Eye: A Platform for Broader Healing

While Sjogren's disease dry eye is the initial target, Stellular Bio's ambitions extend far beyond ophthalmology. The company views its PRB technology as a platform with the potential to address a wide range of conditions characterized by inflammation and a need for tissue regeneration. CEO Derek Adams has pointed to chronic wounds and osteoarthritis as future areas of interest—both massive markets with significant unmet medical needs.

In chronic wound care, such as diabetic foot ulcers, a standardized regenerative biologic could offer a more effective and accessible way to stimulate healing. In osteoarthritis, where patients currently rely on pain management or invasive joint replacement surgery, a PRB therapy could potentially offer a disease-modifying option to repair cartilage and reduce inflammation.

By first proving its concept in a well-defined and underserved patient population, Stellular is building a foundation to expand its "Goldilocks" solution to some of medicine's most challenging and widespread degenerative conditions. The journey for STLR-201 is just beginning, but for millions of patients, it represents a promising new horizon in regenerative medicine.